MLN8054 and Alisertib (MLN8237): Discovery of Selective Oral Aurora A Inhibitors-Reference-Cited by-同舟云学术

MLN8054 and Alisertib (MLN8237): Discovery of Selective Oral Aurora A Inhibitors

Published:2015-05-05 Issue:6 Volume:6 Page:630-634
ISSN:1948-5875
Container-title:ACS Medicinal Chemistry Letters
language:en
Short-container-title:ACS Med. Chem. Lett.

Author:

Sells Todd B.¹,Chau Ryan¹,Ecsedy Jeffrey A.¹,Gershman Rachel E.¹,Hoar Kara¹,Huck Jessica¹,Janowick David A.¹,Kadambi Vivek J.¹,LeRoy Patrick J.¹,Stirling Matthew¹,Stroud Stephen G.¹,Vos Tricia J.¹,Weatherhead Gabriel S.¹,Wysong Deborah R.¹,Zhang Mengkun¹,Balani Suresh K.¹,Bolen Joseph B.¹,Manfredi Mark G.¹,Claiborne Christopher F.¹

Affiliation:

1. Takeda Pharmaceuticals International Co., 40 Landsdowne Street, Cambridge, Massachusetts 02139, United States

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Drug Discovery,Biochemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/ml500409n

Reference23 articles.

1. Aurora kinase inhibitor patents and agents in clinical testing: an update (2011 – 2013)

2. Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase

3. Characterization of Alisertib (MLN8237), an Investigational Small-Molecule Inhibitor of Aurora A Kinase Using Novel In Vivo Pharmacodynamic Assays

4. Discovery, Synthesis, and in Vivo Activity of a New Class of Pyrazoloquinazolines as Selective Inhibitors of Aurora B Kinase

Cited by 78 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical analysis of 10 cases with subcutaneous panniculitis‐like T‐cell lymphoma and tissue AURKA expression;Skin Research and Technology;2024-08

2. High-throughput screening of more than 30,000 compounds for anthelmintics against gastrointestinal nematode parasites;2024-05-18

3. Discovery of a Long Half-Life AURKA Inhibitor to Treat MYC-Amplified Solid Tumors as a Monotherapy and in Combination with Everolimus;Molecular Cancer Therapeutics;2024-04-09

4. Schiff bases and their metal complexes to target and overcome (multidrug) resistance in cancer;European Journal of Medicinal Chemistry;2024-04

5. A comprehensive review on role of Aurora kinase inhibitors (AKIs) in cancer therapeutics;International Journal of Biological Macromolecules;2024-04